HRTX Earnings Prediction
The chart below shows how HRTX performed 10 days before and after its earnings report, based on data from the past quarters. Typically, HRTX sees a +7.06% change in stock price 10 days leading up to the earnings, and a +13.49% change 10 days following the report. On the earnings day itself, the stock moves by +0.45%. This data can give you a slight idea of what to expect for the next quarter's release.
HRTX Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
32.81M
4.38%
-8.92%
Gross Margin
71.17%
69.13%
0.52%
Operating Margin
-13.59%
-82.86%
-24.04%
Net Margin
-14.78%
-81.42%
-42.36%
EPS
-0.03
-82.35%
-50.00%
No Data Available
HRTX Earnings Analysis
Heron Therapeutics, Inc. Corporation (HRTX.O) Earnings Conference Call
Positive
Revenue and Profit Growth: We grew revenues over 12%, improved gross margin from 41% to just over 72%, and doubled gross profit from $37 million to $75 million.
Q4 2024 Revenue Guidance: We have also given a Q4 2024 net revenue guidance range of $37 million to $43 million based on the early success achieved already in Q4.
FDA Approval and Legislation: We received FDA approval of the Vial Access Needle or VAN, on September 24 and we have been included in the final version of the NOPAIN Act which goes into effect in January of 2025.
Gross Profit Improvement: Our product gross profit for the three months ended September 30, 2024, was $23.4 million or 71% which increased from 42% for the same period in 2023.
Gross Profit Improvement: Year-to-date, our product gross profit was $75.1 million or 73%, an increase from 41% for the same period in 2023.
Negative
Revenue Decline Analysis: Total acute care net revenues for the quarter were $7.4 million, while ZYNRRELIEF net revenues for the quarter were $6.3 million, indicating a decline in revenue generation.
Quarterly Revenue Decline: APONVIE net revenues for the quarter were $1.1 million, reflecting a significant drop in sales performance compared to previous periods.
Net Loss Comparison: The net loss was $4.8 million for the three months ended September 30, 2024, compared to $25 million in the same period in 2023, showing a worsening financial position year-over-year.
R&D Expense Decrease: Research and development expenses were $4.5 million and $13.5 million for the three and nine months ended September 30, 2024, compared to $9.3 million and $31.3 million in the comparable periods in 2023, indicating a substantial decrease in investment in innovation.
SG&A Expense Reduction: SG&A expenses for the three and nine months ended September 30, 2024, were $23.3 million and $77.3 million, respectively, compared to $28.8 million and $106.7 million in the same periods in 2023, reflecting a reduction in operational spending but also a potential impact on growth.
HRTX FAQs
How does HRTX typically perform around its earnings report dates?
Is Heron Therapeutics, Inc. (HRTX) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
HRTX Earning Call Sentiment
Heron Therapeutics, Inc. (HRTX) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
HRTX.O
1.79%Positive
The earnings call reveals a mix of positive and negative factors. Financial performance shows improvement, but there's still a net loss and asset impairments, indicating ongoing risks. The lack of a share repurchase program and cash burn concerns weigh negatively. Q&A insights reveal competitive challenges for key products and management's vague responses on certain fronts. Despite some optimistic guidance, the overall sentiment leans negative due to financial risks, competitive pressures, and strategic misalignments.
